Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 612,342 shares of the biopharmaceutical company’s stock, valued at approximately $22,216,000.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Wrapmanager Inc. acquired a new stake in shares of Pfizer during the second quarter worth about $395,000. Global Financial Private Capital LLC raised its holdings in Pfizer by 116.9% during the second quarter. Global Financial Private Capital LLC now owns 322,038 shares of the biopharmaceutical company’s stock worth $11,684,000 after purchasing an additional 173,534 shares in the last quarter. Alps Advisors Inc. raised its holdings in Pfizer by 82.5% during the second quarter. Alps Advisors Inc. now owns 2,583,762 shares of the biopharmaceutical company’s stock worth $93,739,000 after purchasing an additional 1,168,128 shares in the last quarter. Hugh Johnson Advisors LLC raised its holdings in Pfizer by 4.2% during the second quarter. Hugh Johnson Advisors LLC now owns 39,284 shares of the biopharmaceutical company’s stock worth $1,425,000 after purchasing an additional 1,589 shares in the last quarter. Finally, Vicus Capital raised its holdings in Pfizer by 21.5% during the second quarter. Vicus Capital now owns 40,894 shares of the biopharmaceutical company’s stock worth $1,484,000 after purchasing an additional 7,236 shares in the last quarter. Institutional investors and hedge funds own 68.95% of the company’s stock.
Shares of Pfizer stock opened at $44.00 on Friday. Pfizer Inc. has a 12-month low of $33.20 and a 12-month high of $45.81. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The stock has a market capitalization of $262.34 billion, a price-to-earnings ratio of 16.62, a P/E/G ratio of 2.23 and a beta of 0.96.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be issued a $0.34 dividend. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.09%. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.
In other news, insider Laurie J. Olson sold 10,214 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Pfizer Inc acquired 55,556 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were acquired at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the purchase, the insider now owns 21,976,484 shares in the company, valued at $395,576,712. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 234,096 shares of company stock valued at $9,366,617. 0.06% of the stock is currently owned by corporate insiders.
Several research analysts recently issued reports on PFE shares. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday, October 4th. Morgan Stanley set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, August 29th. Credit Suisse Group increased their price target on shares of Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, August 1st. Bank of America increased their price target on shares of Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. Finally, JPMorgan Chase & Co. reissued a “$37.66” rating on shares of Pfizer in a report on Wednesday, July 18th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $42.80.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: Do You Need a Fiduciary?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.